ESSA Pharma Inc. — Investor Relations & Filings

ESSA Pharma Inc. is a clinical-stage pharmaceutical company focused on the development of small molecule drugs for the treatment of prostate cancer. The company's core strategy is to develop novel therapies that target the N-terminal domain (NTD) of the androgen receptor (AR). This approach represents a distinct mechanism of action compared to existing treatments that target the ligand-binding domain of the AR. Its lead clinical candidate, EPI-7386, is an investigational oral drug designed to inhibit AR activity and is being developed for patients with castration-resistant prostate cancer (CRPC), including those whose disease has become resistant to current standard-of-care therapies.